(Q41410278)

30 September 2017

1 reference

title

Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). (English)

1 reference

30 September 2017

1 reference

van Gestel AM

1

1 reference

30 September 2017

Haagsma CJ

series ordinal

2

1 reference

30 September 2017

Furst DE

series ordinal

3

1 reference

30 September 2017

van Riel PL

series ordinal

4

1 reference

30 September 2017

publication date

1 February 1997

1 reference

Bailliere's clinical rheumatology

30 September 2017

published in

1 reference

30 September 2017

volume

11

1 reference

30 September 2017

issue

1

1 reference

30 September 2017

page(s)

65-82

1 reference

Early rheumatoid arthritis--onset, course, and outcome over 2 years

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

The Roche Rheumatology Prize Lecture. The optimal management of early rheumatoid disease: the key to preventing disability

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Combination Therapy in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Does the order of second-line treatment in rheumatoid arthritis matter?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Management of adverse effects of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

Long-term second-line treatment: a prospective drug survival study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

The epidemiology of drug treatment failure in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2897%2980033-7

7 January 2021

10.1016/S0950-3579(97)80033-7

Identifiers

DOI

1 reference

release_klycaapurzgbvbn5t5x5rq7qjq

30 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/klycaapurzgbvbn5t5x5rq7qjq

24 November 2022

mapped directly with Wikidata item

1 reference